Patents by Inventor Larry Gold

Larry Gold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220090080
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Application
    Filed: August 11, 2021
    Publication date: March 24, 2022
    Applicant: SomaLogic, Inc.
    Inventors: Dominic ZICHI, Sheri K WILCOX, Chris BOCK, Daniel J. SCHNEIDER, Bruce EATON, Larry GOLD
  • Patent number: 11221340
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: January 11, 2022
    Assignee: SomaLogic, Inc.
    Inventors: Sheri K. Wilcox, Deborah Ayers, Nebojsa Janjic, Larry Gold, Michael Riel-Mehan, Thale Jarvis
  • Patent number: 11111495
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: September 7, 2021
    Assignee: Somalogic, Inc.
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Patent number: 10648972
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: May 12, 2020
    Assignee: SomaLogic, Inc.
    Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
  • Publication number: 20190330634
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Application
    Filed: May 16, 2019
    Publication date: October 31, 2019
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Patent number: 10422794
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 24, 2019
    Assignee: SomaLogic, Inc.
    Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
  • Publication number: 20190264208
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Application
    Filed: May 16, 2019
    Publication date: August 29, 2019
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Patent number: 10392621
    Abstract: Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: August 27, 2019
    Assignee: SomaLogic, Inc.
    Inventors: Urs A. Ochsner, Louis S. Green, Larry Gold, Nebojsa Janjic
  • Patent number: 10359425
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, Col. 2, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: July 23, 2019
    Assignee: SomaLogic, Inc.
    Inventors: Larry Gold, Marty Stanton, Edward N. Brody, Rachel M. Ostroff, Dominic Zichi, Alex A. E. Stewart
  • Patent number: 10316321
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: June 11, 2019
    Assignee: SomaLogic Inc.
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Publication number: 20180284136
    Abstract: The present disclosure relates to customized therapy for disease. The present disclosure also relates to aptamer-based compositions and methods for identifying, modulating and monitoring drug targets in muscular disease (e.g., Duchenne muscular dystrophy).
    Type: Application
    Filed: January 24, 2018
    Publication date: October 4, 2018
    Applicant: SomaLogic, Inc.
    Inventors: Larry Gold, Robert Kirk DeLisle, David Sterling, Edward Brody, Britta Singer, Robert Mehler
  • Publication number: 20180275143
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
    Type: Application
    Filed: May 30, 2018
    Publication date: September 27, 2018
    Inventors: Sheri K. Wilcox, Deborah Ayers, Nebojsa Janjic, Larry Gold, Michael Riel-Mehan, Thale Jarvis
  • Publication number: 20180259533
    Abstract: The present invention relates to developing customized therapies for a disease or condition in a subject. In particular, the present invention relates to aptamer-based compositions and methods for identifying, modulating and monitoring drug targets in individual with a disease or condition, and further composition and methods for identifying and selecting protein targets for drug development.
    Type: Application
    Filed: September 9, 2016
    Publication date: September 13, 2018
    Applicant: SOMALOGIC, INC.
    Inventors: Larry GOLD, Robert Kirk DELISLE, David STERLING, Rachel OSTROFF, Dom ZICHI
  • Publication number: 20180187197
    Abstract: Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions.
    Type: Application
    Filed: February 13, 2018
    Publication date: July 5, 2018
    Inventors: Urs A. Ochsner, Louis S. Green, Larry Gold, Nebojsa Janjic
  • Publication number: 20180155725
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Application
    Filed: January 23, 2018
    Publication date: June 7, 2018
    Applicant: SomaLogic, Inc.
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Publication number: 20180156787
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).
    Type: Application
    Filed: January 23, 2018
    Publication date: June 7, 2018
    Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
  • Patent number: 9926566
    Abstract: Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: March 27, 2018
    Assignee: SOMALOGIC, INC.
    Inventors: Urs A. Ochsner, Louis S. Green, Larry Gold, Nebojsa Janjic
  • Publication number: 20170137819
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Application
    Filed: January 19, 2017
    Publication date: May 18, 2017
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Publication number: 20160324927
    Abstract: The present disclosure relates to customized therapy for disease. The present disclosure also relates to aptamer-based compositions and methods for identifying, modulating and monitoring drug targets in muscular disease (e.g., Duchenne muscular dystrophy).
    Type: Application
    Filed: May 2, 2016
    Publication date: November 10, 2016
    Inventors: Larry Gold, Kirk DeLisle, David Sterling, Edward Brody, Britta Singer, Robert Mehler
  • Publication number: 20160273033
    Abstract: Techniques, methods, devices, and compositions are disclosed that are useful in identifying and sequencing natural and synthetic, and modified and unmodified DNA, RNA, PNA, DNA/RNA nucleotides. The disclosed techniques, methods, devices, and compositions are useful in identifying various modifications, DNA/RNA damage, and nucleotide structure, using nanoelectronic quantum tunneling spectroscopy, which may be referred to as QM-Seq. The methods and compositions can include the use of a charged, smooth substrate for deposition of single stranded nucleotides and polynucleotide macromolecules, scanning the modified or unmodified DNA/RNA/PNA, comparing the electronic signatures of an unknown nucleobase against a database of electronic fingerprints of known nucleobases, including natural and synthetic, modified and unmodified nucleobases, and secondary/tertiary structure, obtained under the same or similar conditions, for example where the nucleobase is in an acidic environment.
    Type: Application
    Filed: March 16, 2016
    Publication date: September 22, 2016
    Inventor: Larry Gold